tbuckley/cabot-search huggingface dataset:
Hydrophilic Components as Key Active Ingredients in Adipose‐Derived Matrix Bioscaffolds for Inducing Fat Regeneration
Authors: Xiaomu Ma, Qiang Yue, Qian Wang, Chunjun Liu, Su Fu, Jie Luan
Journal: Advanced Healthcare Materials (2024)

Decellularized adipose-derived matrix (DAM) has emerged as a promising biomaterial for soft tissue reconstruction. However, due to a lack of research on its complex composition, the understanding of the key components in DAM remains limited, leading to inconsistent adipogenic properties and challenges in optimizing preparation methods purposefully. In this study, it is proposed for the first time that DAM comprises two distinct components: hydrophilic (H-DAM) and lipophilic (L-DAM), each with markedly different effects on fat regeneration. It is confirmed that H-DAM is the key component for inducing fat regeneration due to its enhanced cell-cell and cell-scaffold interactions, primarily mediated by the Hedgehog signaling pathway. In contrast, L-DAM exhibits poor cell adhesion and contains more antigenic components, leading to a higher immunoinflammatory response and reduced adipogenesis. In addition, it is found that intracellular proteins, which are more abundant in H-DAM, can be retained as beneficial components due to their hydrophilicity, contrary to the conventional view that they shall be removed. Accordingly, a purified bioscaffold with unprecedented efficacy is proposed for fat regeneration and reduced immunogenicity. This finding provides insights for developing scaffolds for fat regeneration and promotes the realization of xenotransplantation.
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures
Authors: Chao Gao, Ran Xiong, Zhi-yu Zhang, Hua Peng, Yuan-kai Gu, Wei Xu, Wei-ting Yang, Yan Liu, Jie Gao, You Yin
Journal: Translational Neurodegeneration (2024)

Abstract The diagnosis of neurodegenerative diseases (NDDs) remains challenging, and existing therapeutic approaches demonstrate little efficacy. NDD drug delivery can be achieved through the utilization of nanostructures, hence enabling multimodal NDD theranostics. Nevertheless, both biomembrane and non-biomembrane nanostructures possess intrinsic shortcomings that must be addressed by hybridization to create novel nanostructures with versatile applications in NDD theranostics. Hybrid nanostructures display improved biocompatibility, inherent targeting capabilities, intelligent responsiveness, and controlled drug release. This paper provides a concise overview of the latest developments in hybrid nanostructures for NDD theranostics and emphasizes various engineering methodologies for the integration of diverse nanostructures, including liposomes, exosomes, cell membranes, and non-biomembrane nanostructures such as polymers, metals, and hydrogels. The use of a combination technique can significantly augment the precision, intelligence, and efficacy of hybrid nanostructures, therefore functioning as a more robust theranostic approach for NDDs. This paper also addresses the issues that arise in the therapeutic translation of hybrid nanostructures and explores potential future prospects in this field.
Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance
Authors: Kun Zhang, Yu‐Jie Zhang, Min Li, Christophe Pannecouque, Erik De Clercq, Shuai Wang, Fen‐Er Chen
Journal: Medicinal Research Reviews (2024)

Abstract The pivotal involvement of reverse transcriptase activity in the pathogenesis of the progressive HIV virus has stimulated gradual advancements in drug discovery initiatives spanning three decades. Consequently, nonnucleoside reverse transcriptase inhibitors (NNRTIs) have emerged as a preeminent category of therapeutic agents for HIV management. Academic institutions and pharmaceutical companies have developed numerous NNRTIs, an essential component of antiretroviral therapy. Six NNRTIs have received Food and Drug Administration approval and are widely used in clinical practice, significantly improving the quality of HIV patients. However, the rapid emergence of drug resistance has limited the effectiveness of these medications, underscoring the necessity for perpetual research and development of novel therapeutic alternatives. To supplement the existing literatures on NNRTIs, a comprehensive review has been compiled to synthesize this extensive dataset into a comprehensible format for the medicinal chemistry community. In this review, a thorough investigation and meticulous analysis were conducted on the progressions achieved in NNRTIs within the past 8 years (2016–2023), and the experiences and insights gained in the development of inhibitors with varying chemical structures were also summarized. The provision of a crucial point of reference for the development of wide‐ranging anti‐HIV medications is anticipated.
Transcatheter tricuspid valve intervention versus medical therapy for symptomatic tricuspid regurgitation: a meta-analysis of reconstructed time-to-event data
Authors: Guangguo Fu, Jianfu Zhu, Wenyu Song, Ghufran Bagaber, Chunsheng Wang, Jinmiao Chen, Lai Wei
Journal: International Journal of Surgery (2024)

Background: Transcatheter tricuspid valve intervention (TTVI) has demonstrated safety and efficacy in treating high-risk patients with tricuspid regurgitation (TR). The authors aimed to perform a meta-analysis based on reconstructed time-to-event data to compare the clinical benefit of TTVI with medical therapy (MED). Methods: A systematic literature search was conducted in major databases, including PubMed, Embase, and the Cochrane Library, until 20 October 2023. All studies comparing the outcomes between TTVI and MED were included. The primary outcome was all-cause mortality. The secondary outcomes included heart failure (HF) hospitalization and the composite outcome of all-cause mortality and HF hospitalization. Results: Five studies covering 3826 patients (1146 received TTVI and 2680 received MED) were identified. At 1-year follow-up, TTVI significantly reduced the risk of all-cause mortality compared with MED [hazard ratio (HR) 0.54, 95% CI: 0.39–0.74, P =0.0001]. There was a trend in favor of TTVI in HF hospitalization, although without significant difference (HR 0.70, 95% CI: 0.42–1.18, P =0.18). TTVI was also associated with a decreased risk of composite outcome (HR 0.57, 95% CI: 0.38–0.86, P =0.007). Reconstructed Kaplan–Meier curves illustrated a 1-year overall survival rate of 83.1% in the TTVI group and 68.8% in the MED group. The subgroup analysis of device types yielded consistent results. Conclusions: Compared with MED, TTVI was associated with greater 1-year benefits for patients with symptomatic moderate or greater TR from the aspects of all-cause mortality and HF hospitalization.
Risk of Developing Inflammatory Arthritis in Psoriasis Patients Initiating Treatment With Biologics: A Population Based Analysis
Authors: Bruce Strober, Ahmed M. Soliman, Chao Li, Manish Patel, Ikenna Unigwe, Paolo Gisondi
Journal: Journal of the American Academy of Dermatology (2024)

The relationship between biologic treatments for psoriasis (PsO) and the development of inflammatory arthritis in patients is not fully understood.
Mutual Amplification of <scp>GLI2</scp>/Hedgehog and Transcription Factor <scp>JUN</scp>/<scp>AP</scp>‐1 Signaling in Fibroblasts in Systemic Sclerosis: Potential Implications for Combined Therapies
Authors: Christina Bergmann, Sara Chenguiti Fakhouri, Trinh‐Minh Thuong, Tim Filla, Aleix Rius Rigau, Arif B. Ekici, Benita Merlevede, Ludwig Hallenberger, Honglin Zhu, Clara Dees, Alexandru‐Emil Matei, Janina Auth, Andrea‐Hermina Györfi, Xiang Zhou, Simon Rauber, Aline Bozec, Nicholas Dickel, Chunguang Liang, Meik Kunz, Georg Schett, Jörg H.W. Distler
Journal: Arthritis & Rheumatology (2024)

Deregulation of the cJUN/AP-1 and hedgehog/GLI2 signaling pathways has been implicated in fibroblast activation in systemic sclerosis (SSc). However, the consequences of their concomitant up-regulation are unknown. Here, we tested the hypothesis that mutual amplification of both pathways might drive persistent fibroblast activation.
Relapse prediction in <scp>ANCA</scp>‐associated vasculitis
Authors: Eithne Nic an Ríogh, Mark A. Little
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Reply
Authors: Meiqi Xing, Yudiyang Ma, Feipeng Cui, Dankang Li, Jianing Wang, Linxi Tang, Lei Zheng, Jian Yang, Yaohua Tian
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
A randomized controlled trial analyzing nonthermal atmospheric plasma for the treatment of verruca vulgaris in pediatric patients
Authors: Courtney L. Walker, Chelsea N. Shope, Laura A. Andrews, Kelly M. Atherton, Tyler Beck, Gabriella Santa Lucia, Gregory Fridman, Peter C. Friedman, Colleen H. Cotton, Lara Wine Lee
Journal: Journal of the American Academy of Dermatology (2024)
An overview of the functions and mechanisms of APOBEC3A in tumorigenesis
Authors: Yuqi Yang, Nan Liu, Likun Gong
Journal: Acta Pharmaceutica Sinica B (2024)

The APOBEC3 (A3) family plays a pivotal role in the immune system by performing DNA/RNA single-strand deamination. Cancers mostly arise from the accumulation of chronic mutations in somatic cells, and recent research has highlighted the A3 family as a major contributor to tumor-associated mutations, with A3A being a key driver gene leading to cancer-related mutations. A3A helps to defend the host against virus-induced tumors by editing the genome of cancer-associated viruses that invade the host. However, when it is abnormally expressed, it leads to persistent, chronic mutations in the genome, thereby fueling tumorigenesis. Notably, A3A is prominently expressed in innate immune cells, particularly macrophages, thereby affecting the functional state of tumor-infiltrating immune cells and tumor growth. Furthermore, the expression of A3A in tumor cells may directly affect their proliferation and migration. A growing body of research has unveiled that A3A is closely related to various cancers, which signifies the potential significance of A3A in cancer therapy. This paper mainly classifies and summarizes the evidence of the relationship between A3A and tumorigenesis based on the potential mechanisms, aiming to provide valuable references for further research on the functions of A3A and its development in the area of cancer therapy.
Examining Blood Pressure Changes with Spironolactone for Alopecia: A Retrospective Analysis
Authors: Deesha Desai, Ambika Nohria, Michelle Sikora, Nnaemeka Anyanwu, Avrom S Caplan, Michael Garshick, Jerry Shapiro, Kristen I Lo Sicco
Journal: Journal of the American Academy of Dermatology (2024)
Commentary on “Totally Laparoscopic Versus Laparoscopy-Assisted Distal Gastrectomy: The Klass-07, A Randomized Controlled Trial”
Authors: Banwari L. Bairwa, Ayush Anand, Nathnael A. Woldehana, Prakasini Satapathy, Shilpa Gaidhane, Quazi S. Zahiruddin, Sarvesh Rustagi
Journal: International Journal of Surgery (2024)
Assessment of SWI/SNF chromatin remodeling complex related genes as potential biomarkers and therapeutic targets in pan-cancer
Authors: Kai Zhuang, Lishan Wang, Chengyu Lu, Zhiping Liu, Dongli Yang, Hao Zhong, Jiami Zou, Aamir Fahira, Jiaojiao Wang, Zunnan Huang
Journal: Molecular Cancer (2024)

Recent research has uncovered a surprisingly high occurrence of aberrant expression and mutations in the genes that encode subunits of the SWI/SNF chromatin-remodeling complexes (SCRC). Nevertheless, the carcinogenic effects of aberrant expression and mutations in SWI/SNF genes have only been acknowledged in recent times, resulting in a comparatively limited understanding of these modifications. In this study, we comprehensively analyzed the expression difference, somatic mutation, potential biological pathways, stromal or immune cell infiltration, and drug sensitivity of SCRC-related genes (SCRGs) in pan-cancer. Furthermore, the evolutionary trend, prognostic signature, and immunotherapy response of SCRGs in kidney renal clear cell carcinoma (KIRC) were also evaluated. The expression of SCRGs was changed in 13 out of 14 tumor types, strongly linked to prognosis, and mutated in 30.9% of tumor patients. SCRGs were also closely associated with immune-related pathways and tumor metastasis pathways. The expression of SCRGs was positively associated with the immune score or stromal score but negatively correlated with Tumor purity. Three potential drugs (FK866, Ispinesib mesylate, and WZ3105) were identified to target the SCRGs. In KIRC, scRNA-seq analysis showed that the enrichment of SCRC and the communication frequency with immune cells were significantly declined during tumor cell progression. A prognostic signature was constructed in KIRC and was effective in predicting the prognosis for KIRC. Aberrant expression of eleven prognostic genes identified from the KIRC prognostic signature and the cytotoxicity of FK866 and Ispinesib mesylate to KIRC were verified by qRT-PCR and CCK-8 assay, respectively. Our study identified SCRGs as potential biomarker and therapeutic targets, providing new insights into SCRC for tumor-targeted therapy.
Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN)
Authors: Valentin Goutaudier, Richard Danger, Rusan Ali Catar, Maud Racapé, Aurélie Philippe, Michelle Elias, Marc Raynaud, Olivier Aubert, Didier Bouton, François Girardin, Éric Vicaut, Sarhan Yaiche, Jacques Demotes, Harald Heidecke, Jean-Luc Taupin, Christine Randoux-Lebrun, Mohamad Zaidan, Emmanuelle Papuchon, Hoa Le Mai, Thi-Van-Ha Nguyen, Francesc Moreso, Thierry Berney, Jean Villard, Christophe Legendre, Duska Dragun, Vassilios Papalois, Luciano Potena, Magali Giral, Pierre-Antoine Gourraud, Sophie Brouard, Elena Crespo, Fabian Halleck, Klemens Budde, Oriol Bestard, Alexandre Loupy, Carmen Lefaucheur
Journal: Kidney International (2024)

Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020. We prospectively assessed gene expression levels of 19 blood messenger RNAs, four antibodies targeting non–human leukocyte antigen (HLA) endothelial antigens, together with circulating anti-HLA donor-specific antibodies (DSA). The primary outcome was allograft rejection (antibody-mediated, T cell–mediated, or mixed) in the first year post-transplantation. Overall, 412 patients were included, with 812 biopsies paired with a blood sample. <i>CD4</i> gene expression was significantly associated with rejection, while circulating anti-HLA DSA had a significant association with allograft rejection and a strong association with antibody-mediated rejection. All other tested biomarkers, including <i>AKR1C3, CD3E, CD40, CD8A, CD9, CTLA4, ENTPD1, FOXP3, GZMB, ID3, IL7R, MS4A1, MZB1, POU2AF1, POU2F1, TCL1A, TLR4</i>, and <i>TRIB1</i>, as well as antibodies against angiotensin II type 1 receptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations with allograft rejection. The blood messenger RNAs and non-HLA antibodies did not show an additional value beyond standard of care monitoring parameters and circulating anti-HLA DSA to predict allograft rejection in the first year post-transplantation. Thus, our results open avenues for specifically designed studies to demonstrate the clinical relevance and implementation of other candidate non-invasive biomarkers in kidney transplantation practice.
Transapical beating heart septal myectomy learning curve and training of future surgeons: an observational study
Authors: Jiangtao Li, Yue Chen, Rui Li, Jing Fang, Eduard Quintana, Xiang Wei
Journal: International Journal of Surgery (2024)

Description of the learning curve for transapical beating heart septal myectomy (TA-BSM) helps to understand the potential for wider adaptability. The authors elaborate and examine a competency-based training assessment for TA-BSM that could serve to disseminate septal myectomy expertise. Data on 177 consecutive patients who underwent the TA-BSM for hypertrophic obstructive cardiomyopathy (HOCM) between April 2022 and June 2023 was collected prospectively, which was registered on ClinicalTrials.gov. Using the cumulative sum analysis, the authors identified two distinct learning phases based on the procedural time. Outcomes of procedural success and major complications were also compared between phases. Assessment through a Likert scale competency-based assessment of a myectomy surgeon after on-site TA-BSM training. The cumulative sum analysis of procedural time showed two well-differentiated phases: the initial phase (cases 1-44) and the proficiency phase (cases 45-177). After 44 cases, significant improvements in procedural time were observed (113 vs. 134 min; P<0.001). Optimal procedural success (left ventricular outflow tract gradient <30 mmHg and mitral regurgitation grade ≤1+ without mortality or median sternotomy conversion) increased in the proficiency phase (93.2 vs. 79.5%; P=0.018), while complications decreased. The assessment of another surgeon showed consistent agreement in operative decision-making and performance for all evaluated domains. Competence in TA-BSM was achieved after 44 cases, without sacrificing guideline-desired outcomes. Appropriate training of other septal myectomy surgeons could further expedite this learning curve. This new technique may represent an option for wider dissemination of HOCM surgery worldwide and improve disease management.
Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling study
Authors: Antoine Brault, Isabelle Pontais, Vincent Enouf, Christine Debeuret, Emma Bloch, Juliette Paireau, Marie-Anne Rameix-Welti, Michael White, Gaëlle Baudemont, Bruno Lina, Isabelle Parent du Châtelet, Jean-Sébastien Casalegno, Sophie Vaux, Simon Cauchemez
Journal: The Lancet Child & Adolescent Health (2024)
Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case–control study in Paris, France
Authors: Ricardo Carbajal, Pierre-Yves Boelle, Aurélie Pham, Yoann Chazette, Mathilde Schellenberger, Clara Weil, Anne-Sophie Colas, Thibault Lecarpentier, Aurélie Schnuriger, Romain Guedj, Mathie Lorrot, Harriet Corvol, Maxime Enault
Journal: The Lancet Child & Adolescent Health (2024)
Oropouche virus genomic surveillance in Brazil
Authors: Filipe Romero Rebello Moreira, João Victor Rodrigues Dutra, André Henrique Barbosa de Carvalho, Clarisse Rezende Reis, Jéssica Silqueira Hickson Rios, Marisa de Oliveira Ribeiro, Monica Barcellos Arruda, Patricia Alvarez, Renan Pedra Souza, Carolina Voloch, Danielle Alves Gomes Zauli, Renato Santana Aguiar
Journal: The Lancet Infectious Diseases (2024)
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
Authors: Ioannis Parodis, Julius Lindblom, Roger A Levy, Margherita Zen, Nursen Cetrez, Alvaro Gomez, Shereen Oon, Christine Henning, Munther Khamashta, Holly A Quasny, Deven Chauhan, Anca Askanase, Ronald van Vollenhoven, Mandana Nikpour
Journal: The Lancet Rheumatology (2024)
Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial
Authors: George M Solomon, Rachel W Linnemann, Rachel Rich, Ashleigh Streby, Brian Buehler, Eric Hunter, Kadambari Vijaykumar, William R Hunt, John J Brewington, Andras Rab, Shasha P Bai, Adrianna L Westbrook, Carmel McNicholas-Bevensee, Jong Hong, Candela Manfredi, Cristina Barilla, Shingo Suzuki, Brian R Davis, Eric J Sorscher
Journal: The Lancet Respiratory Medicine (2024)
Europe needs to urgently implement an outward looking Global Health Strategy
Authors: Astrid Berner-Rodoreda, Quique Bassat, Alberto Rocamora, Mario Raviglione, Ana B Abecasis, Kerstin Klipstein-Grobusch, Jolene Skordis, Nora Anton, Till Bärnighausen
Journal: The Lancet Regional Health - Europe (2024)
Targeting toll-like receptor 7 as a therapeutic development strategy for systemic lupus erythematosus
Authors: Meng Wang, Hekai Chen, Tuan Zhang, Zhikuan Zhang, Xuwen Xiang, Meng Gao, Yilan Guo, Shuangshuang Jiang, Kejun Yin, Mintao Chen, Jian Huang, Xincheng Zhong, Umeharu Ohto, Jing Li, Toshiyuki Shimizu, Hang Yin
Journal: Acta Pharmaceutica Sinica B (2024)

Endosomal TLRs (TLR3/7/8/9) are highly analogous innate immunity sensors for various viral or bacterial RNA/DNA molecular patterns. Among them, TLR7, in particular, has been suggested to be a target for various inflammatory disorders and autoimmune diseases including systemic lupus erythematosus (SLE); but few small-molecule inhibitors with elaborated mechanism have been reported in literature. Here, we reported a well-characterized human TLR7-specific small-molecule inhibitor, TH-407b, with promising potency and negligible cytotoxicity through a novel binding mechanism. Notably, TH-407b not only effectively inhibited TLR7-mediated pro-inflammatory signaling in a variety of cultured cell lines but also demonstrated potent inflammation suppressing activities in primary peripheral blood mononuclear cells (PBMCs) derived from SLE patients. Furthermore, TH-407b showed prominent efficacy in vivo, improved survival rate and ameliorated symptoms of SLE model mice. To obtain molecular insights into the TH-407b derivatives' inhibition mechanism, we performed the structural analysis of TLR7/TH-407b complex using cryogenic electron microscopy (cryo-EM) method. As an atomistic resolution cryo-EM structure of the TLR family, it not only of value to facilitate structure-based drug design, but also shed light to methodology development of small proteins using EM. Significantly, TH-407b has unveiled an inhibition strategy for TLR7 via stabilizing its resting/inactivated state. Such a resting state could be generally applicable to all TLRs, rendering a useful method for targeting this group of important immunological receptors.
Clinical Images: A large disfiguring nasal mass and progressive dyspnea
Authors: Renato Ferrandiz‐Espadin, Sonal Choudhary, Didem Saygin
Journal: Arthritis & Rheumatology (2024)

Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Disclosure form Supplementary Figure 1: The nasal mass after 3 months of treatment. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.